Transferrin receptor-mediated transport at the blood-brain barrier is elevated during early development and maintained across aging and in an Alzheimer's mouse model.

ABSTRACT: Transferrin receptor (TfR)-targeting of biologics has emerged as a promising strategy to improve drug delivery across the blood-brain barrier (BBB). However, most preclinical studies evaluating TfR-enabled drugs have been conducted in young adult animals. It remains unclear whether age and aging-related diseases impact TfR protein levels and/or BBB transport capacity. Here, we utilized a previously described TfR-targeting antibody transport vehicle (ATV^TfR) to investigate how healthy aging and disease progression in the 5xFAD mouse model of Alzheimer's disease (AD) impact TfR protein and TfR-mediated brain delivery. ATV^TfR transport capacity remained stable across 3- to 24-month-old healthy mice and 5xFAD progression did not impair ATV^TfR brain transport up

SUBMITTER: Torres VO 

PROVIDER: S-EPMC12357843 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature